What states are actually doing about compounded GLP-1s and peptides
Most coverage of peptide legality argues about federal law. The enforcement that has actually closed businesses and pulled products in the last two years has been at the state level, and it has not used drug scheduling to do it.
The two enforcement theories, and why the distinction matters to you
If you are trying to work out whether something is "legal," scheduling is the wrong thing to look at. Here is what is actually being used:
- Consumer protection (attorney general). The claim is not that the compound is a controlled substance — it is that selling it was an unfair or deceptive trade practice, often paired with unlicensed practice of pharmacy. Connecticut has run this play four times. The remedies are injunctions, monetary penalties, and occasionally personal liability for executives.
- Licensure and possession (pharmacy board). The claim is that a licensee possessed or used something it was not permitted to, or that no valid prescriber relationship existed. This is faster and blunter: Ohio suspends licences without a prior hearing when it finds evidence of immediate and serious harm.
Neither requires a legislature to act, which is why this has moved much faster than the federal Category 2 process our categories explainer covers.
Verified state actions
11 actions across 6 states, each opened and quoted at the primary source.
The Board's published suspension list runs from 17 January 2025 through 4 August 2026 and is dominated by med spas, aesthetics clinics, IV-hydration providers and men's-health and testosterone clinics. Suspensions issue without a prior hearing on clear and convincing evidence of a danger of immediate and serious harm. The Board's own February 2026 newsletter puts the count at "more than 30" as of that date.
Why it matters: This is the most aggressive licensing-board program we found anywhere, and it targets exactly the clinic model that sells peptides alongside aesthetics.
Signed 22 May 2026, effective 1 August 2026, enacting La. R.S. 37:23.5. It bars state licensing boards from prohibiting prescribers and pharmacies from providing peptides — but only where the pharmacy is already in compliance with 21 U.S.C. 353a. An earlier draft tied the protection to a peptide not being on the FDA Category 2 list; the sponsor's own floor amendment deleted that language before passage.
Why it matters: The compliance condition is the whole story. BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon have no USP monograph, are not components of approved drugs, and are not on the federal bulks list — so they cannot satisfy 353a, and the shield never engages for them. Louisiana did not deregulate peptides; it protected conduct that was already lawful. The law also binds only Louisiana licensing boards, not the FDA, the DOJ, or a plaintiff.
The most directly peptide-targeted state pronouncement we found. It also requires active ingredient to come from an establishment registered with the FDA and licensed both in Washington and in its own resident state.
Why it matters: Names research peptides explicitly rather than reaching them by implication, and adds a dual-licensure requirement most suppliers cannot meet.
The platform must halt US sales, deploy a monitoring system, and remove listings within five days. Penalty of $300,000, suspended after $30,000. Announced alongside a settlement with a Connecticut med spa over advertising and prescribing non-FDA-approved compounded semaglutide and tirzepatide.
Why it matters: The relief reaches nationwide, not just Connecticut — one state's consumer-protection settlement changed what buyers anywhere could order from that seller.
The Board states that no clinic should order, possess, or administer any drug labelled for research purposes only, that doing so violates state and federal law "regardless if the patient 'consents'," and that such stock must be disposed of immediately with patients advised to stop. Inspectors specifically named retatrutide and cagrilintide. The same document says BPC-157 and other Category 2 and 3 bulk substances cannot be compounded, and that adding bacteriostatic saline to an unfinished product is itself compounding and must meet compounding rules.
Why it matters: The clearest statement any regulator has published that the RUO label does not create a lawful route for a clinic, and that a consent form does not fix it.
A full repeal-and-replace of the compounding regulations at 16 CCR 1735-1738. Section 1736.9(d) requires the certificate of analysis to give the name and address of the manufacturer, not merely a distributor, and an ingredient without it may not be used. Section 1736.9(e) bars components labelled not for human use. The "essentially a copy" test is stricter than the federal one: the pharmacist must independently verify and document a clinically significant, patient-specific difference.
Why it matters: The manufacturer-naming rule attacks the exact opacity that lets unregistered material enter the supply chain. Note the scope limit — the certificate rule applies to sterile compounding.
A $300,000 judgment, suspended after payment of $18,500, with the company's chief executive personally liable for the full amount if the agreement is breached.
Why it matters: Personal liability for an executive is unusual in this space and signals how the state viewed the conduct.
Products labelled research use only, or made by establishments not registered with the FDA, may not be used for compounding in any circumstance. Existing retatrutide and cagrilintide inventory must be disposed of immediately. Semaglutide and tirzepatide salt forms are treated as different active ingredients than the approved drugs and are prohibited. Ohio adds a state-specific requirement that all active ingredient be purchased from Ohio-licensed distributors.
Why it matters: Names the two compounds currently driving the gray market and forecloses them at the pharmacy level, not just the clinic level.
Filed under the Connecticut Unfair Trade Practices Act plus unlicensed practice of pharmacy, with a civil investigative demand to an online marketplace. Warning letters went to weight-loss clinics and med spas stating that advertising and selling these compounded medications may violate CUTPA, and singling out providers who claim the drugs are FDA-approved or are "generic" versions of the brand products.
Why it matters: The theory here is consumer protection and unlicensed pharmacy — not drug scheduling. That is the template other states are most likely to copy.
Three boards jointly stated that identifying a physician or advanced practice clinician as a medical director, on staff, or available is insufficient to establish the valid practitioner-patient relationship required before prescribed drugs are administered. The prescriber must personally evaluate and diagnose the patient and make the treatment recommendation.
Why it matters: This goes directly at the figurehead-prescriber structure used by many direct-to-consumer platforms and med spas.
Nevada's administrative code places human growth hormone on Schedule III outright and lists chorionic gonadotropin within its Schedule III anabolic steroid entries. The rule dates to 1982 as amended through 2017 — longstanding background law, not a recent development. Nevada statute also directs the Board to schedule any product used to enhance athletic performance, muscle mass, strength or weight without medical necessity, language broad enough on its face to reach growth-hormone secretagogues, though we found no evidence the Board has applied it to them.
Why it matters: The clearest example that state drug law and federal drug law diverge on peptide hormones. Federally, HGH is not scheduled.
What to watch next: The ALEC model bill
A model policy titled the American Peptide Access Act was finalised by the American Legislative Exchange Council on 12 August 2026. Its title clause is verbatim identical to Louisiana's, but it is structurally different in the way that matters: it defines a peptide as a polymer of fewer than 40 amino acids, expressly names BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax and Epitalon — precisely the seven that are not on the federal bulks list — and contains no reference to 21 U.S.C. 353a, no reference to Category 2, and no federal-compliance condition at all.
Read the model policy →
What we confirmed is not the case
Negative findings are worth as much as positive ones here, because the peptide internet is full of confident claims in both directions.
| Finding | Basis |
|---|---|
| No state we checked schedules any GLP-1 | Semaglutide, tirzepatide, retatrutide and cagrilintide are handled as prescription or unapproved drugs, not controlled substances. |
| No state we checked schedules research peptides | BPC-157, ipamorelin, CJC-1295 and MK-677 appear in no schedule we read. Restriction happens through pharmacy-board possession and compounding rules instead. |
| Illinois and Florida do not schedule peptide hormones | We read both states' Schedule III text in full and found no growth hormone, somatropin, or chorionic gonadotropin entry. |
| Ohio does not require an in-person visit for compounded GLP-1s or peptides | Ohio's in-person-visit authority is tied to Schedule II controlled substances, which these are not. Ohio also expressly permits asynchronous telehealth, subject to meeting the in-person standard of care. |
Reported but not yet verified
These come from a named law-firm survey whose underlying citations we could not open at the primary source. We list them so you know where to look, and we are not treating them as established until we have read the documents ourselves.
| State | Reported action |
|---|---|
| Washington | Pharmacy commission stop-service order on a GLP-1 sterile compounder, reported as March 2025. |
| California | Rewritten Board of Pharmacy compounding regulations effective 1 October 2025, reported to require a documented clinically significant patient-specific difference and to require the certificate of analysis to name the active-ingredient manufacturer rather than the distributor. |
| Illinois | Attorney General consumer alert on compounded GLP-1s, reported as January 2025. |
| South Carolina | Attorney General consumer alert on compounded GLP-1s, reported as January 2025. |
| Alabama | Medical board declaratory ruling on physician-office compounding, reported as August 2024 — notable for reaching office compounding through the medical board rather than the pharmacy board. |
| Oregon, Kansas, Kentucky, West Virginia, New Jersey | Pharmacy board statements on semaglutide compounding, reported across 2023 to 2025. |
What this means if you are buying
- The RUO label protects the seller, not you. Ohio's position is that a clinic possessing RUO product is in violation regardless of consent. If a provider is administering something labelled research use only, the legal exposure is theirs and the medical exposure is yours.
- "A doctor oversees it" may mean nothing. Three Ohio boards jointly said a named medical director who never evaluates you does not create a prescriber relationship. Ask who actually reviewed your intake, by name.
- Retatrutide and cagrilintide are the current flashpoint. A state board has ordered existing inventory destroyed. Anyone still selling them is operating against explicit written guidance.
- Your state may differ. We verified three states deeply and could not survey the rest. Your state pharmacy board's website is the authoritative source, and it is usually searchable.
Regulatory news
PCAC voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List on narrow margins (BPC-157 8–6); DSIP was voted down. FDA staff had recommended against inclusion, and the committee is advisory — the FDA's final call is still pending.
Our Legal-Status Tracker, updated →The most-watched peptide of the reclassification clears its first regulatory hurdle. Category 2 removal is separate from 503A compounding eligibility — two different tracks.
The two-track explainer →The reversal of the 2023 restrictions began here. The FDA's formal updated list remains unpublished; every row of our tracker updates the day it drops.
The Legal-Status Tracker →All tracked news → · Fed by a daily automated scan; entries publish only after primary-source verification.
Regulatory journalism, not legal or medical advice, and not a substitute for checking your own state's rules. Enforcement in this area is moving quickly; each item is dated and linked to its source, and corrections land in our changelog.